Prevention and treatment of rheumatoid arthritis
AssigneeStolle Research & Development Corporation
InventorsRalph J. Stolle, Lee R. Beck
Life of this patent
Estimating the term…
Abstract
There is disclosed a novel method and product for the treatment and prevention of rheumatoid arthritis. The method involves passive immunization against a mixed spectrum of infectious bacteria which reside in the human gastrointestinal tract. The passive immunization is accomplished by oral injestion of IgG immunoglobulin obtained from the milk of cows that have been immunized against a specific spectrum of bacterial types. A unique combination of bacterial species is formulated into a vaccine which is used to immunize dairy cattle. The IgG antibody obtained from the milk of the immunized cows constitutes the product of the invention.
Claims4
A method for the treatment of rheumatoid arthritis caused by a mixed spectrum of infectious bacteria which reside in the gastrointestinal tract, including:
- ______________________________________ ORGANISMS ______________________________________ Staphylococcus aureus Staphylococcus epidermidis Streptococcus pyogenes, A. Type 1 Streptococcus pyogenes, A. Type 3 Streptococcus pyogenes, A. Type 5 Streptococcus pyogenes, A. Type 8 Streptococcus pyogenes, A. Type 12 Streptococcus pyogenes, A. Type 14 Streptococcus pyogenes, A. Type 18 Streptococcus pyogenes, A. Type 22 Aerobacter aerogenes Escherichia coli Salmonella enteritidis Pseudomonas aeruginosa Klebsiella pneumoniae Salmonella typhimurium Haemophilus influenzae Streptococcus viridans Proteus vulgaris Shigella dysenteriae Streptococcus, Group B Diplococcus pneumoniae Streptococcus mutans Corynebacterium, Acne, Types 1 & 2 ______________________________________
- which comprises the oral administration of a quantity of non-fat milk solids equivalent to one quart of immunized cow's milk IgG, post-prandially two times daily, wherein the cow's milk IgG includes antibodies produced by the following microorganisms from American Type Culture Collection bacterial antigens:
- ______________________________________ ORGANISMS *ATCC NO. ______________________________________ Staphylococcus aureus 11631 Staphylococcus epidermidis 155 Streptococcus pyogenes, A. Type 1 8671 Streptococcus pyogenes, A. Type 3 10389 Streptococcus pyogenes, A. Type 5 12347 Streptococcus pyogenes, A. Type 8 12349 Streptococcus pyogenes, A. Type 12 11434 Streptococcus pyogenes, A. Type 14 12972 Streptococcus pyogenes, A. Type 18 12357 Streptococcus pyogenes, A. Type 22 10403 Aerobacter aerogenes 884 Escherichia coli 26 Salmonella enteritidis 13076 Pseudomonas aeruginosa 7700 Klebsiella pneumoniae 9590 Salmonella typhimurium 13311 Haemophilus influenzae 9333 Streptococcus viridans 6249 Proteus vulgaris 13315 Shigella dysenteriae 11835 Streptococcus, Group B Diplococcus pneumoniae Streptococcus mutans Corynebacterium, Acne, Types 1 & 2 ______________________________________
An antibody for the treatment of rheumatoid arthritis caused by a mixed spectrum of infectious bacteria which reside in the gastrointestinal tract, including:
- ______________________________________ ORGANISMS ______________________________________ Staphylococcus aureus Staphylococcus epidermidis Streptococcus pyogenes, A. Type 1 Streptococcus pyogenes, A. Type 3 Streptococcus pyogenes, A. Type 5 Streptococcus pyogenes, A. Type 8 Streptococcus pyogenes, A. Type 12 Streptococcus pyogenes, A. Type 14 Streptococcus pyogenes, A. Type 18 Streptococcus pyogenes, A. Type 22 Aerobacter aerogenes Escherichia coli Salmonella enteritidis Pseudomonas aeruginosa Klebsiella pneumoniae Salmonella typhimurium Haemophilus influenzae Streptococcus viridans Proteus vulgaris Shigella dysenteriae Streptococcus, Group B Diplococcus pneumoniae Streptococcus mutans Corynebacterium, Acne, Types 1 & 2 ______________________________________
- produced by first preparing a vaccine from killed bacteria from the American Type Culture Collection bacterial antigens, including:
- ______________________________________ Staphylococcus aureus 11631 Staphylococcus epidermidis 155 Streptococcus pyogenes, A. Type 1 8671 Streptococcus pyogenes, A. Type 3 10389 Streptococcus pyogenes, A. Type 5 12347 Streptococcus pyogenes, A. Type 8 12349 Streptococcus pyogenes, A. Type 12 11434 Streptococcus pyogenes, A. Type 14 12972 Streptococcus pyogenes, A. Type 18 12357 Streptococcus pyogenes, A. Type 22 10403 Aerobacter aerogenes 884 Escherichia coli 26 Salmonella enteritidis 13076 Pseudomonas aeruginosa 7700 Klebsiella pneumoniae 9590 Salmonella typhimurium 13311 Haemophilus influenzae 9333 Streptococcus viridans 6249 Proteus vulgaris 13315 Shigella dysenteriae 11835 Streptococcus, Group B Diplococcus pneumoniae Streptococcus mutans Corynebacterium, Acne, Types 1 & 2 ______________________________________
- injecting said vaccine intramuscularly in healthy cows once weekly for four consecutive weeks, and twice monthly thereafter, each injection involving 20.times.10.sup.8 bacterial cells;
- collecting the milk from the immunized cows beginning the fourth week;
- and testing fro titer to insure that the minimum titer against each of the bacteria is 1-500, as determined by the tube agglutination method for testing antibody titer.
Dependencies are inferred from the claim text.